Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 3/20 | 0.57 |
| ▸ | GLO1 | Q04760 | 9/20 | 0.46 |
| ▸ | MMP2 | P08253 | 3/20 | 0.45 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.41 |
| ▸ | ACLY | P53396 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3982725 | 0.81 | METAP2 (0.74) | METAP2GLO1MMP2 | |
| SCHEMBL6197982 | 0.78 | METAP2 (0.54) | METAP2GLO1MMP2SLC40A1ACLY | |
| SCHEMBL3979202 | 0.75 | METAP2 (0.58) | METAP2GLO1MMP2BRAF | |
| SCHEMBL6199983 | 0.74 | METAP2 (0.45) | METAP2GLO1MMP2 | |
| SCHEMBL3983775 | 0.73 | METAP2 (1.00) | METAP2GLO1MMP2SLC40A1 | |
| SCHEMBL5070604 | 0.70 | KCNA5 (0.71) | METAP2GLO1 | |
| SCHEMBL14301394 | 0.70 | KCNA5 (0.71) | METAP2GLO1 | |
| SCHEMBL3987166 | 0.69 | METAP2 (0.49) | METAP2GLO1MMP2 | |
| SCHEMBL15359703 | 0.69 | SLC40A1 (0.52) | METAP2GLO1MMP2SLC40A1 | |
| SCHEMBL3981921 | 0.68 | METAP2 (0.85) | METAP2GLO1MMP2SLC40A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1549613-A1 | SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY | Abbott Laboratories (US) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004033419-A1 | SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY | ABBOTT LABORATORIES (US) | 2004-04-22 | — | — | WO | disclosed |